Published Online
on March 9, 2006

A more recent version of this article appeared on April 1, 2006

This Article Full Text (PDF) All Versions of this Article: 37/4/1070    most recent 01.STR.0000208294.46968.a4v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Birman-Deych, E. Articles by Gage, B. F. Search for Related Content PubMed PubMed Citation Articles by Birman-Deych, E. Articles by Gage, B. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Medicare Hazardous Substances DB WARFARIN

Submitted on November 14, 2005
Accepted on January 10, 2006

Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation

Elena Birman-Deych MS; Martha J. Radford MD; David S. Nilasena MD, MSPH, MS; and Brian F. Gage MD, MS^*

From the Washington University School of Medicine (E.B.-D., B.F.G.), St. Louis, Mo; New York University School of Medicine (M.J.R.), New York, NY; Centers for Medicare and Medicaid Services (D.S.N.), Dallas, Tex.

^* To whom correspondence should be addressed. E-mail: bgage{at}im.wustl.edu.

Background and Purpose--More than 2 million Americans have atrial fibrillation, and without antithrombotic therapy, their stroke rate is increased 5-fold. In randomized controlled trials, warfarin prevented 65% of ischemic strokes (hazard ratio [HR], 0.35; 95% CI, 0.26 to 0.48) compared with no antithrombotic therapy. However, the effectiveness of warfarin therapy outside of clinical trials is unknown, especially in black and Hispanic populations. Our goal was to quantify use of warfarin therapy, frequency of International Normalized Ratio monitoring, and effectiveness for stroke prophylaxis in Medicare beneficiaries with atrial fibrillation.

Methods--This was a cohort study of Medicare beneficiaries with atrial fibrillation who were hospitalized between March 1998 and April 1999 in all 50 US states. The primary outcome was incident hospitalizations for ischemic stroke based on validated International Classification of Diseases, 9th Revision, Clinical Modification codes.

Results--Two thirds of ideal anticoagulation candidates were prescribed warfarin on hospital discharge. In unadjusted analyses, the stroke rates per 100 patient years of warfarin therapy were 5.2 in (non-Hispanic) white Medicare beneficiaries, 10.6 in black beneficiaries, and 12.2 in Hispanic beneficiaries. After adjusting for comorbid conditions, warfarin prescription was more frequent and monitoring more regular in white Medicare beneficiaries than in black or Hispanic beneficiaries (P<0.0001). Warfarin use was associated with 35% fewer ischemic strokes (HR, 0.65; 95% CI, 0.55 to 0.76) compared with no antithrombotic therapy but was less effective in black and Hispanic beneficiaries (P for interaction=0.048).

Conclusions--The use, monitoring, and effectiveness of warfarin therapy are suboptimal in Medicare beneficiaries, especially in black and Hispanic beneficiaries.

Key words: atrial fibrillation • continental population groups • stroke • warfarin

This article has been cited by other articles:

				A. Y.-J. Shen, J. F. Yao, S. S. Brar, M. B. Jorgensen, X. Wang, and W. Chen Racial/Ethnic Differences in Ischemic Stroke Rates and the Efficacy of Warfarin Among Patients With Atrial Fibrillation Stroke, October 1, 2008; 39(10): 2736 - 2743. [Abstract] [Full Text] [PDF]

				D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]

				S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Response to Letter Regarding Article, "Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation" Circulation, February 5, 2008; 117(5): e150 - e150. [Full Text] [PDF]

				G. A. Ford, A. M. Choy, P. Deedwania, D. G. Karalis, C.-J. Lindholm, W. Pluta, L. Frison, S. B. Olsson, and on behalf of the SPORTIF III, V Investigators Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trials Stroke, November 1, 2007; 38(11): 2965 - 2971. [Abstract] [Full Text] [PDF]

				S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation Circulation, July 24, 2007; 116(4): 449 - 455. [Full Text] [PDF]